Endometrial cancer is the sixth most common cancer in women worldwide. While the majority of patients present with early stage disease at diagnosis, efficacious therapeutic options for advanced or recurrent disease are scarce. Apart from the combination of Keytruda and Lenvima approved for treatment of certain patient subpopulations, endometrial cancer is predominantly treated with generic chemotherapy. Lack of efficacious treatment options across numerous treatment settings presents enormous market opportunity for drug developers to address with development of targeted therapeutics.
- What is the current standard of care for endometrial cancer? What are interviewed experts’ insights on current treatment options? What are the main unmet needs?
- What are the most promising agents in the late-phase pipeline and most notable in early-phase pipeline? How will these agents shape the future of the endometrial cancer market?
- How are current therapies reimbursed? What are the key market access considerations for emerging therapies?
- What are the drivers and constraints of the market?
Markets covered: United States, France, Germany, United Kingdom, and Japan.
Primary research: 3 KOL interviews in the United States, 1 each in France, Germany, United Kingdom and Japan.
Key companies covered: Merck & Co., Eisai, AstraZeneca,GlaxoSmithKline, Roche, Karyopharm Therapeutics and others.
Key drugs covered: Keytruda, Imfinzi, Tecentriq, dostarlimab, Lenvima, Xpovio, Lyparza and others.
Product description: Executive Insights provides indication-specific market intelligence with world class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
- Endometrial Carcinoma - Executive Insights - Executive Insights
- Endometrial Cancer | US-EU-JP | Executive Insights - 2020
Author(s): Anamika Ghosh, Ph.D.
Anamika Ghosh, M.Sc., Ph.D., is a manager on the Oncology team at DRG, part of Clarivate. She has expertise in various solid and hematological malignancies and immune-oncology drug classes, such as immune checkpoint inhibitors and CAR T-cell therapies. As a Ph.D. and postdoctoral fellow at the International Centre for Genetic Engineering and Biotechnology (ICGEB), Dr. Ghosh studied host-pathogen interactions during Mycobacterium tuberculosis and Dengue virus infections. She received her Ph.D. in life sciences from ICGEB and an M.Sc. in biomedical sciences from the University of Delhi.